NESMOS Department, Sapienza University of Rome, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Rome, Italy.
Department of Neuropsychiatry, Villa Von Siebenthal Neuropsychiatric Hospital, Genzano Di Roma, Italy.
Expert Opin Pharmacother. 2021 Aug;22(11):1407-1416. doi: 10.1080/14656566.2021.1910236. Epub 2021 Apr 13.
: Long-acting injectable (LAI) antipsychotic drugs are developed to reduce daily intake need and to overcome treatment non-adherence. Aripiprazole IM depot refers to two long-acting aripiprazole formulations, once monthly monohydrate (AOM) and aripiprazole lauroxil. AOM has been approved for schizophrenia since 2012 and for bipolar disorder since 2017. Aripiprazole lauroxil is approved for schizophrenia, not for bipolar disorder.: To assess the effect of AOM in bipolar disorder, the authors searched PubMed and ClinicalTrials.gov for randomized trials using AOM in patients with bipolar disorder. Included were four studies covering efficacy, functioning, quality of life, and safety/tolerability. Studies lasted 12 months.: AOM reduced symptoms of patients with bipolar disorder and a manic episode, increased functioning and quality of life, and protected from recurrence of manic episodes. It proved to be safe/tolerable, with only akathisia occurring in ≥10% of cases and more frequently than with placebo. However, there were only 143 patients receiving AOM in the considered studies. Included studies were backed in their conclusions by other literature, but they come from 2017-2018. No studies are expected or planned in the near future. Aripiprazole lauroxil has not applied for approval in bipolar disorder and there is no sign it will.
长效注射（LAI）抗精神病药物旨在减少每日摄入量需求并克服治疗不依从性。阿立哌唑 IM depot 是两种长效阿立哌唑制剂，每月一次一水合物（AOM）和阿立哌唑月桂酰。AOM 自 2012 年以来已被批准用于精神分裂症，自 2017 年以来已被批准用于双相情感障碍。阿立哌唑月桂酰已被批准用于精神分裂症，不适用于双相情感障碍。
为了评估 AOM 在双相情感障碍中的疗效，作者在 PubMed 和 ClinicalTrials.gov 上搜索了使用 AOM 治疗双相情感障碍患者的随机试验。纳入了四项研究，涵盖了疗效、功能、生活质量和安全性/耐受性。研究持续 12 个月。
AOM 可减轻双相情感障碍患者和躁狂发作的症状，提高功能和生活质量，并预防躁狂发作的复发。它被证明是安全/耐受的，只有静坐不能的发生率≥10%，且比安慰剂更常见。然而，在考虑的研究中，只有 143 名患者接受了 AOM 治疗。纳入的研究在其结论中得到了其他文献的支持，但这些研究来自 2017-2018 年。预计或计划在不久的将来不会进行研究。阿立哌唑月桂酰尚未在双相情感障碍中申请批准，也没有迹象表明它将被批准。
